Brief: Iveric Bio Reports First Quarter 2022 Financial Results

IVERIC bio

04/05/2022 13:33

May 4 (Reuters) - Iveric Bio Inc  ISEE.O :
    * IVERIC BIO REPORTS FIRST QUARTER 2022 OPERATIONAL
HIGHLIGHTS AND
FINANCIAL RESULTS
    * QTRLY LOSS PER SHARE $0.29
    * Q1 EARNINGS PER SHARE VIEW $-0.29 -- REFINITIV IBES DATA
    * ESTIMATES ITS YEAR-END 2022 CASH, CASH EQUIVALENTS AND
AVAILABLE-FOR-SALE SECURITIES TO RANGE BETWEEN $215 AND $225
MILLION
    * AS OF MARCH 31, 2022, COMPANY HAD APPROXIMATELY $345.7
MILLION
IN CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES
    * PLANS TO INITIATE A CLINICAL TRIAL STUDYING ZIMURA IN
PATIENTS
WITH INTERMEDIATE AMD IN Q4 OF 2022
    * EXPECTS TO SUBMIT AN INVESTIGATIONAL NEW DRUG APPLICATION
(IND)
TO FDA FOR IC-500 DURING MID-2023
    * IVERIC BIO-SEES THAT CASH, CASH EQUIVALENTS &
AVAILABLE-FOR-SALE
SECURITIES TO BE SUFFICIENT TO FUND REQUIREMENTS & OPERATING
EXPENSES THROUGH MID-2024

Source text for Eikon:  ID:nBwb95kjVa 
Further company coverage:  ISEE.O 

 ((reuters.briefs@thomsonreuters.com;))